menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Inhibrx Wins Trade Secret Case, Reaffirms Commitment to Innovation

    PR NEWSWIRE

    Sanofi completes acquisition of Inhibrx, Inc.

    PRESS RELEASE

    Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

    PR NEWSWIRE

    Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

    PRESS RELEASE

    Arecor to retain Inhibrx royalties in wake of Sanofi acquisition

    PRESS RELEASE

    Inhibrx Announces Sale of INBRX-101 to Sanofi for value of up to $2.2B

    PR NEWSWIRE

    Inhibrx Reports Third Quarter 2023 Financial Results

    PR NEWSWIRE

    Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109

    PR NEWSWIRE

    Inhibrx Announces Participation in Upcoming Scientific Conferences

    PR NEWSWIRE

    Inhibrx Announces $200 Million Private Placement Financing

    PR NEWSWIRE

    Inhibrx Granted Fast Track for INBRX-101 for Alpha-1 Antitrypsin Deficiency

    PR NEWSWIRE

    Inhibrx Reports 1Q 2023 FYR and Recent Corporate Highlights

    PR NEWSWIRE

    Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD

    PR NEWSWIRE

    Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

    PR NEWSWIRE

    NorthStar Medical Radioisotopes and Inhibrx Enter Collaboration

    CONTRACT PHARMA

    Inhibrx Announces Participation in Upcoming Investor Conference

    PRESS RELEASE

    Inhibrx Announces Updated Efficacy and Safety Data Ph1 Trial of INBRX-109

    PRNEWSWIRE

    Inhibrx Reports Third Quarter 2022 Financial Results and Corporate Highlights

    PRNEWSWIRE

    Inhibrx Jumps After Possibility of FDA Approval for INBRX-101

    TIPRANKS

    Inhibrx Announces Opportunity for Approval for INBRX-101

    PRESS RELEASE

    Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

    SEEKINGALPHA

    Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101

    PRNEWSWIRE

    EMA Grants ODD to INBRX-109 for the Treatment of Chondrosarcoma

    PRNEWSWIRE

    Inhibrx Reports Q2 2022 Financial Results and Recent Corporate Highlights

    PRNEWSWIRE

    Inhibrx concludes Phase I dose escalation of solid tumour therapy

    PRESS RELEASE

    INBRX-101 Shows Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency

    PRNEWSWIRE

    Inhibrx To Host Webcast of Topline Results from the PI Trial of INBRX-101

    PRESS RELEASE

    Inhibrx Reports First Quarter 2022 Financial Results

    PRESS RELEASE

    Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?

    NASDAQ

    Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101

    PRNEWSWIRE

    US FDA grants orphan drug status to Inhibrx’s AATD treatment

    PHARMACEUTICAL-TECHNOLOGY

    Inhibrx Selects Genialis ResponderID for Clinical Optimization Study, INBRX-109

    BUSINESSWIRE

    Inhibrx announces initial results from phase 1 trial of INBRX-106 + Keytruda

    PHARMABIZ

    Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma

    BIOSPACE

    Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

    PRNEWSWIRE

    Inhibrx shares rise on PhI trial results; Braglia`s Helsinn partners with Fosun

    ENDPTS

    INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin

    BIOSPACE

    Inhibrx To Host Webcast Presentation on Phase 1 Trial of INBRX-101 Result

    PRNEWSWIRE

    Inhibrx Granted Fast Track Designation for INBRX-109

    BIOSPACE

    Inhibrx Announces Ph 1 Dose Escalation Results INBRX-106,Hexavalent OX40 Agonist

    PRNEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.